Punicalagin attenuates ventricular remodeling after acute myocardial infarction via regulating the NLRP3/caspase-1 pathway.
Pharm Biol
; 61(1): 963-972, 2023 Dec.
Article
in En
| MEDLINE
| ID: mdl-37357417
ABSTRACT
CONTEXT Punicalagin has myocardial protection; the mechanism of punicalagin on ventricular remodeling (VR) after acute myocardial infarction (AMI) remains unclear. OBJECTIVE:
These studies explore the role and mechanism of punicalagin in preventing and treating VR after AMI. MATERIALS ANDMETHODS:
Molecular docking was used to predict the targets of punicalagin. After 2 weeks of AMI model, the SD rats were randomly divided into model, and punicalagin (200, 400 mg/kg, gavage) groups for 4 weeks. Thoracotomy with perforation but no ligature was performed on rats in control group. The protein expression of nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing 3 (NLRP3), apoptosis speck-like protein (ASC), caspase-1, gasdermin D (GSDMD), and GSDMD-N, the mRNA expression of NLRP3, caspase-1, GSDMD, interleukin-1ß (IL-1ß) and IL-18 were evaluated.RESULTS:
Punicalagin had binding activities with NLRP3 (Vina score, -5.8), caspase-1 (Vina score, -6.7), and GSDMD (Vina score, -6.7). Punicalagin could improve cardiac function, alleviate cardiac pathological changes, minimize the excessive accumulation of collagen in the left ventricular myocardium (p < 0.01), and inhibit cardiomyocyte apoptosis (p < 0.01). Furthermore, punicalagin could inhibit the overexpression of NLRP3, caspase-1, and GSDMD via immunohistochemistry (p < 0.01). Punicalagin inhibited the protein levels of NLRP3, caspase-1, ASC, GSDMD, and GSDMD-N (p < 0.05, p < 0.01). Punicalagin reduced the mRNA expression of NLRP3, caspase-1, GSDMD, IL-1ß and IL-18 (p < 0.05, p < 0.01).CONCLUSIONS:
Punicalagin may provide a useful treatment for the future myocardial protection.Key words
Full text:
1
Database:
MEDLINE
Main subject:
Signal Transduction
/
Ventricular Remodeling
/
Hydrolyzable Tannins
/
Myocardial Infarction
Type of study:
Prognostic_studies
Limits:
Animals
Language:
En
Journal:
Pharm Biol
Year:
2023
Type:
Article
Affiliation country:
China